Did you know that gastroesophageal reflux disease (GERD) remains one of the most prevalent gastrointestinal disorders worldwide, with significant implications for healthcare systems and patient quality of life? Understanding the evolving landscape of GERD pathophysiology, diagnosis, and treatment can help identify therapeutic gaps and innovation opportunities.
GERD is a common but complex condition. It is caused by dysfunction of the lower esophageal sphincter (LES), which prevents gastric contents from refluxing into the esophagus. When this sphincter weakens or relaxes inappropriately, acid and bile irritate the esophageal lining. While occasional reflux is physiologically normal, GERD is diagnosed when this backflow occurs frequently or causes mucosal damage and uncomfortable symptoms such as heartburn, chest pain, chronic cough, laryngitis, and asthma-like symptoms.
Symptom severity, however, does not always correlate with esophageal damage. For patients with typical symptoms, initial empiric proton pump inhibitor (PPI) therapy is often both diagnostic and therapeutic. However, persistent symptoms or alarm features (e.g., dysphagia, weight loss, bleeding) warrant further investigation. PPIs are highly effective in erosive disease, but have been known to lead to nutrient malabsorption, microbiome alterations, and chronic kidney disease. Other treatment mechanisms include H2 receptor antagonists, which are useful for mild disease or nocturnal breakthrough symptoms, and antacids and alginate formulations, which offer rapid, short-term symptom relief.
As with most everyday complaints, the world of small molecule drugs will come to the rescue. Phathom Pharmaceuticals’ Voquezna (vonoprazan) is gaining traction in some markets through faster and longer acting acid suppression compared to empiric PPI therapy.
In Europe, linaprazan glurate, a potassium-competitive acid blocker (P-CAB) and a prodrug of linaprazan, was originally developed by AstraZeneca. Now licensed and manufactured by Cinclus Pharma, Sweden, linaprazan glurate also offers a rapid onset of action and sustained acid suppression. Currently in phase II clinical studies, linaprazan glurate has demonstrated its potential to provide more effective and consistent acid control, addressing the limitations observed with PPIs, such as delayed onset and variable efficacy.
Following news of a recent commercialization partnership with Zentiva, Cinclus Pharma has granted rights to commercialize and manufacture linaprazan glurate across Europe, including the UK, Switzerland, and the European Economic Area. The partnership aims to expedite linaprazan glurate's European market entry, enhancing treatment options for gastric acid-related diseases.
Targeting visceral hypersensitivity, enhancing mucosal defense, or modulating esophageal motility could represent future frontiers in GERD therapeutics. The pipeline is also exploring drug-device hybrids, novel esophageal mucosal protectants, and probiotics as gut-brain axis modulators.
GERD may be a familiar clinical entity, but its multifactorial nature and the limitations of current therapies continue to challenge patients and providers. However, there remains room for innovation,from refining acid suppression to developing therapies that address motility, sensitivity, and mucosal defense.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
